New research in The FASEB Journal suggests that a chimera design of DNA and small DNA with a companion contrast agent to facilitate uptake allows antibodies to cross cell membranes
Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes. Once across these membranes, the tissues being evaluated can be imaged a much greater level of detail than what is possible now.
This could significantly impact the use of gene therapy and stem cell therapy, as well as lead to better diagnosis and treatment of cancer, Alzheimer’s disease, viral infections, HIV, herpes and prion diseases.
“Dr. McCoy does not have to perform a biopsy to know the disorder and cure patients without surgery in Star Trek,” said Philip K. Liu, Ph.D., a researcher involved in the work from the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital in Charlestown, Massachusetts. “This finding avoids biopsy and it makes a ‘McCoy diagnosis’ one step closer to reality.”
To make this advance, Liu and colleagues used three groups of mice. This first group received a complete chimera (antibodies to rhodopsin linked to a reporter agent and small DNA), the second group received a chimera without DNA. A third group had damaged retinas and a less rhodopsin. The first group showed a presence of the chimera in the retina using MRI (in vivo) or TEM (ex vivo). Uptake and targeting of complete chimera were compared in the third group and the first group. Results showed that the third group had significantly less uptake of chimera.
“There will be a time when biopsies are considered primitive,” said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, “and as developments in imaging technology and techniques improve our capabilities, the need for invasive, and sometimes painful, biopsies is greatly decreased.”
The Latest on: Invasive biopsies
via Google News
The Latest on: Invasive biopsies
- Study Highlights Potential Advantages of Tape Strips Over Biopsyon August 13, 2020 at 5:52 am
The concept of using adhesive strips to remove surface skin cells for clinical study has been around for more than 20 years, but there has been recent progress.
- Global Liquid Biopsy Market Size, Share to grow with 21.54% CAGR through 2027on August 13, 2020 at 5:34 am
Selbyville, Delaware According to Market Study Report, Provides A Detailed Overview Of Liquid Biopsy Market With Respect To The Pivotal Drivers Influencing The Revenue Graph Of This Business Sphere.
- Micronoma Launches with $3 Million Seed Fundingon August 13, 2020 at 4:05 am
PRNewswire/ -- Micronoma, an early cancer-detection biotech that seeks to develop and commercialize a minimally invasive, microbiome-based method, ...
- Developing a blood test for prostate canceron August 13, 2020 at 2:57 am
Professor Pockley among researchers from the John van Geest Cancer Research Centre have recently developed a blood test for the detection of prostate cancer.
- Comprehensive retinal vascular measurements: a novel association with renal function in type 2 diabetic patients in Chinaon August 13, 2020 at 2:14 am
To examine the association between various retinal vascular measurements and microalbuminuria in patients with type 2 diabetes in a northwestern China study. Data from 911 patient ...
- Cervical Cancer Drugs Market Research Report by Indication, by Treatment Type, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19on August 11, 2020 at 6:20 am
Cervical Cancer Drugs Market Research Report by Indication (Advanced Invasive Stage, Early Invasive Stage, and Pre-malignant Lesions), ...
- FDA approves Guardant’s next-gen, tumor-sequencing blood teston August 10, 2020 at 5:15 am
Guardant Health received a milestone approval from the FDA for its cancer test, as the first liquid biopsy able to genetically profile solid tumors anywhere in the body through a single blood draw.
- miR Scientific Announces Validation of its Urine Based, Non-Invasive Prostate Cancer Test Published in the Journal of Urologyon August 10, 2020 at 4:30 am
Validated Data Reinforces Capability to Molecularly Detect and Characterize Prostate Cancer with Concurrent Sensitivity and Specificity of Over 91% - Data Support Integration of Sentinel Prostate ...
- FDA OKs Liquid Biopsy to Identify EGFR-Positive Lung Canceron August 7, 2020 at 2:29 pm
The FDA on Friday approved the Guardant360 CDx assay to identify metastatic lung cancer patients who carry specific EGFR mutations, making them eligible for upfront treatment with osimertinib ...
- FDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic Teston August 7, 2020 at 12:27 pm
Generation Sequencing Companion Diagnostic TestPR NewswireSILVER SPRING, Md. 7, 2020 /PRNewswire/ -- Today, the U.
via Bing News